Fundraising Fox
Palvellatx
NASDAQ: PVLAWayne, US · Founded 2015 · 55 employees on LinkedIn · 4 known investors
Find your way into Palvellatx
Sign up to see every warm intro you have to Palvellatx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Palvellatx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Palvella Therapeutics develops QTORIN™, a targeted topical formulation of rapamycin designed to treat rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations by delivering the active ingredient to the dermal layers with minimal systemic absorption.
Founders & leadership
Palvellatx was founded in 2015 by Wesley H. Kaupinen.
Investors · 4
How we know: BioAdvance's portfolio page · Not right? Tell us
How we know: Frazier Life Sciences's portfolio page · Not right? Tell us
How we know: Samsara BioCapital's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Palvellatx do?
- Palvella Therapeutics develops QTORIN™, a targeted topical formulation of rapamycin designed to treat rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations by delivering the active ingredient to the dermal layers with minimal systemic absorption.
- Who founded Palvellatx?
- Palvellatx was founded by Wesley H. Kaupinen in 2015.
- Who are Palvellatx's investors?
- Palvellatx's investors include BioAdvance, Frazier Life Sciences, Samsara BioCapital, Agent Capital.
- Where is Palvellatx headquartered?
- Palvellatx is headquartered in Wayne, US.